RxDoctor Payments DataLook up a doctor →

Cristin Bruns, MD

Endocrinology, Diabetes & Metabolism · Tulsa, OKNPI 1053364224

Payments from drug & device makers

$158,924in general payments, 2019–2025

Across 426 payments — averaging $373.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$48K
  • Novo Nordisk$35K
  • AstraZeneca$24K
  • Lilly USA, LLC$22K
  • Abbott$21K
  • AbbVie$6K
  • plus $3K from 28 others

What the payments were for

  • Consulting fees$8,4435%
  • Speaking & faculty fees$139,38988%
  • Travel & lodging$4,4973%
  • Food & beverage$6,4464%
  • Education$1490%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$158,924 in reported general payments places this provider in the 90th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.

See all endocrinology, diabetes & metabolism providers in Oklahoma

Medicare billing

Part B allowed, 2024
$13,110
Medicare patients
95
Services billed
217

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide94$89,213
JardianceEmpagliflozin81$49,065
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog57$46,873
Tresiba Flextouch U-100Insulin Degludec62$23,941
MounjaroTirzepatide21$23,565
Humalog Kwikpen U-200Insulin Lispro11$17,553
Tresiba Flextouch U-200Insulin Degludec11$6,167
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog39$5,998
Fiasp FlextouchInsulin Aspart (Niacinamide)13$4,706
SynthroidLevothyroxine Sodium126$3,408
Novolog FlexpenInsulin Aspart40$3,035
Droplet Pen NeedlePen Needle, Diabetic32$1,582
NovologInsulin Aspart11$1,385
Novolin NInsulin Nph Human Isophane12$652
Insulin SyringeSyringe-Needle,insulin,0.5 Ml15$628

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$34,775$90,597105 claims
Boehringer IngelheimJardiance$48,396$49,06581 claims
Lilly USA, LLCMounjaro$21,675$23,56521 claims
AbbVieSynthroid$6,473$3,408126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.

Other endocrinology, diabetes & metabolism in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →